Drugs for Lung Cancer

Table. Drugs Prescribed for Lung Cancer

• Drug name (generic name)
• Drug company
• Indications
• Patient support services

Drug name (generic name)
• Abraxane (paclitaxel protein-bound particles; albumin-bound)
Drug company
• Bristol Myers Squibb
Indication
• Treatment of locally advanced or metastatic NSCLC, in combination with carboplatin
Patient support services
• BMS Oncology Co-Pay Assistance Program
  800-861-0048
  
  Bristol Myers Squibb Patient Assistance Foundation
  800-736-0003

Drug name (generic name)
• Alecensa (alectinib) Capsules
Drug company
• Genentech
Indication
• Treatment of metastatic NSCLC with ALK mutation
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Alimta (pemetrexed) Injection
Drug company
• Eli Lilly
Indication
• Treatment of locally advanced or metastatic nonsquamous NSCLC, as first-line treatment, with cisplatin, or as maintenance treatment
Patient support services
• Lilly Oncology Infused Products Co-pay Program
  866-472-8663
  
  Lilly Cares Foundation Patient Assistance Program
  800-545-6962

Drug name (generic name)
• Alunbrig (brigatinib) Tablets
Drug company
• Takeda Oncology
Indication
• Treatment of metastatic NSCLC with ALK mutation
Patient support services
• Takeda Oncology Co-Pay Assistance Program
  844-817-6468
  
  Takeda Oncology Patient Assistance Program
  844-817-6468

Drug name (generic name)
• Avastin (bevacizumab) Injection
Drug company
• Genentech
Indication
• Treatment of nonsquamous NSCLC, in combination with carboplatin and paclitaxel
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Cosela (trilaciclib) Injection
Drug company
• G1 Therapeutics
Indication
• To reduce the frequency of chemotherapy-induced myelosuppression in adults with extensive-stage small-cell lung cancer
Patient support services
• G1 Commercial Copay Program
  877-821-2465
  
  Patient Assistance Program
  833-418-6663

Drug name (generic name)
• Cyramza (ramucirumab) Injection
Drug company
• Eli Lilly
Indication
• First-line treatment, in combination with Tarceva, of metastatic NSCLC and EGFR exon 19 deletions or exon 21 (L858R) substitution mutations
  
  Treatment, in combination with docetaxel, of metastatic NSCLC whose disease progressed during or after platinum-based chemotherapy
Patient support services
• Cyramza Savings Card
  866-472-8663
  
  Lilly Cares Foundation Patient Assistance Program
  800-545-6962

Drug name (generic name)
• Enhertu (fam-trastuzumab) Injection
Drug company
• Daiichi Sankyo/ AstraZeneca
Indication
• Treatment of adult patients with unresectable or metastatic NSCLC with activating HER2 (ERBB2) mutations, who have received a prior systemic therapy
Patient support services
• Enhertu Patient Savings Program
  833-364-3788
  
  Enhertu Patient Assistance Program
  833-364-3788

Drug name (generic name)
• Exkivity (mobocertinib) Capsules
Drug company
• Takeda Oncology
Indication
• Treatment of adults with locally advanced or metastatic NSCLC and EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose NSCLC progressed during or after platinum-based chemotherapy
Patient support services
• Takeda Oncology Co-Pay Assistance Program
  844-817-6468
  
  Takeda Oncology Patient Assistance Program
  844-817-6468

Drug name (generic name)
• Gavreto (pralsetinib) Capsules
Drug company
• Genentech
Indication
• Treatment of metastatic NSCLC and RET fusions
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Gilotrif (afatinib) Tablets
Drug company
• Boehringer Ingelheim
Indication
• Treatment of patients with metastatic NSCLC and EGFR exon 19 deletions or exon 21 L958R substitution
  
  Treatment of patients with advanced squamous-cell carcinoma of the lung whose disease progressed after platinum-based chemotherapy
  
  First-line treatment for metastatic NSCLC and non-resistant EGFR mutations L861Q, G719X, and S768I
Patient support services
• Gilotrif Plus Co-pay Assistance Program
  877-546-5349
  
  Gilotrif Bridge Program
  877-546-5349
  
  Gilotrif Dose Exchange Program
  877-546-5349
  
  BI Cares Foundation Patient Assistance Program
  855-297-5904

Drug name (generic name)
• Hycamtin (topotecan) injection
Drug company
• Novartis
Indication
• Small-cell lung cancer with platinum-sensitive disease progressing after first-line chemotherapy
Patient support services
• Novartis Patient Assistance Foundation
  800-277-2254
  
  Patient Assistance Now Oncology
  800-282-7630

Drug name (generic name)
• Imjudo (tremelimumab) & Imfinzi (durvalumab)
Drug company
• AstraZeneca
Indication
• Imjudo, in combination with Imfinzi, and platinum-based chemotherapy for adult patients with metastatic NSCLC with no sensitizing EGFR mutation or ALK genomic tumor aberrations
Patient support services
• Imfinzi Co-pay Savings Program
  
  AZ&Me Prescription Savings Program
  800-292-6363

Drug name (generic name)
• Imfinzi (durvalumab)
Drug company
• AstraZeneca
Indication
• Patients with stage III nonresectable NSCLC that has not progressed after chemoradiation
Patient support services
• Imfinzi Co-pay Savings Program
  844-275-2360
  
  AZ&Me Prescription Savings Program
  800-292-6363

Drug name (generic name)
• Iressa (gefitinib) Tablets
Drug company
• AstraZeneca
Indication
• Metastatic NSCLC with EGFR exon 19 deletions or exon 21 substitution mutations
Patient support services
• IRESSA Co-pay Savings Program
  844-275-2360
  
  AZ&Me Prescription Savings Program
  800-292-6363

Drug name (generic name)
• Keytruda (pembrolizumab)
Drug company
• Merck
Indication
• First-line treatment of metastatic or stage III nonresectable NSCLC with high PD-L1 and no EGFR or ALK mutations
  
  Metastatic NSCLC expressing PD-L1 and disease progression during or after platinum-containing chemotherapy; patients with EGFR or ALK mutations should have disease progression during an FDA-approved therapy for these mutations before using Keytruda
  
  Metastatic nonsquamous NSCLC, as first-line treatment, in combination with carboplatin and paclitaxel or Abraxane
  
  First-line treatment, in combination with pemetrexed and platinum, of metastatic nonsquamous NSCLC and no EGFR or ALK mutations
  
  Treatment of metastatic small-cell lung cancer progressing during or after platinum-based chemotherapy and at least 1 other therapy
Patient support services
• Merck Co-pay Assistance Program
  855-257-3932
  
  Merck Patient Assistance Program
  855-257-3932

Drug name (generic name)
• Libtayo (cemiplimab-rwlc) Injection
Drug company
• Regeneron/Sanofi Genzyme
Indication
• First-line treatment of NSCLC with high PD-L1 expression, as determined by an FDA-approved test, and no EGFR, ALK, or ROS1 aberrations in patients with locally advanced NSCLC who are not candidates for surgical resection or for definitive chemoradiation therapy
  
  First-line treatment of NSCLC with high PD-L1 expression, as determined by an FDA-approved test, and no EGFR, ALK, or ROS1 aberrations in patients with metastatic NSCLC
Patient support services
• Libtayo Surround Commercial Copay Program
  877-542-8296
  
  Libtayo Surround Patient Assistance Program
  877-542-8296

Drug name (generic name)
• Lorbrena (lorlatinib) Tablets
Drug company
• Pfizer
Indication
• Metastatic NSCLC and ALK mutation progressing with crizotinib, alectinib, or ceritinib therapy
Patient support services
• Pfizer Oncology Together Co-Pay Savings Program
  877-744-5675
  
  Pfizer Patient Assistance Program
  877-744-5675

Drug name (generic name)
• Lumakras (sotorasib) Tablets
Drug company
• Amgen
Indication
• Treatment of adults with locally advanced or metastatic NSCLC and KRAS G12C mutation after 1 or more systemic therapies
Patient support services
• Amgen FIRST STEP Co-Pay Program
  866-264-2778
  
  Amgen Safety Net Foundation
  866-264-2778

Drug name (generic name)
• Mekinist (trametinib) & Tafinlar (dabrafenib)
Drug company
• Novartis
Indication
• Metastatic NSCLC with BRAF V600E or V600K mutations
Patient support services
• Novartis Oncology Universal Co-pay Program
  877-577-7756
  
  Patient Assistance Now Oncology
  800-282-7630
  
  Novartis Patient Assistance Foundation
  800-277-2254

Drug name (generic name)
• Mvasi (bevacizumab-awwb)
Drug company
• Amgen
Indication
• First-line treatment of unresectable, locally advanced, recurrent or metastatic nonsquamous NSCLC, in combination with carboplatin and paclitaxel
Patient support services
• Amgen FIRST STEP Co-Pay Program
  866-264-2778
  
  Amgen Safety Net Foundation
  866-264-2778

Drug name (generic name)
• Opdivo (nivolumab)
Drug company
• Bristol Myers Squibb
Indication
• First-line treatment, in combination with Yervoy, of metastatic NSCLC and PD-L1 expression, as determined by an FDA-approved test, and no EGFR or ALK mutations
  
  Treatment, in combination with Yervoy and 2 cycles of chemotherapy, of metastatic or recurrent NSCLC and no EGFR or ALK mutations
  
  Treatment of metastatic NSCLC that progressed during or after platinum-based chemotherapy
  
  First-line treatment, in combination with Yervoy, of unresectable malignant pleural mesothelioma (cancer of the lining of the lungs)
  
  Treatment, with platinum-doublet chemotherapy, for adult patients with resectable NSCLC in the neoadjuvant setting
Patient support services
• BMS Oncology Co-Pay Assistance Program
  800-861-0048
  
  Bristol Myers Squibb Patient Assistance Foundation
  800-736-0003

Drug name (generic name)
• Photofrin (porfimer)
Drug company
• Pinnacle Biologics
Indication
• Endobronchial NSCLC
Patient support services
• Photofrin Patient Assistance Program
  855-215-2720

Drug name (generic name)
• Portrazza (necitumumab)
Drug company
• Eli Lilly
Indication
• Metastatic squamous NSCLC, in combination with gemcitabine and cisplatin
Patient support services
• Lilly Cares Foundation Patient Assistance Program
  800-545-6962

Drug name (generic name)
• Retevmo (selpercatinib) Capsules
Drug company
• Eli Lilly
Indication
• Treatment of NSCLC and RET mutations or fusions
  
  Treatment of locally advanced or metastatic NSCLC with a RET gene fusion
Patient support services
• Retevmo Savings Card
  866-472-8663
  
  Lilly Cares Foundation Patient Assistance Program
  800-545-6962

Drug name (generic name)
• Rozlytrek (entrectinib) Capsules
Drug company
• Genentech
Indication
• Treatment of metastatic NSCLC with ROS1 mutation
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Rybrevant (amivantamab-vmjw) Injection
Drug company
• Janssen Biotech
Indication
• Treatment of adults with locally advanced or metastatic NSCLC and EGFR exon 20 insertion mutation whose NSCLC progressed during or after platinum-based chemotherapy
Patient support services
• Janssen CarePath Savings Program
  833-792-7382
  

Drug name (generic name)
• Tabrecta (capmatinib) Tablets
Drug company
• Novartis
Indication
• Treatment of metastatic NSCLC
  
  Treatment of adult patients with metastatic NSCLC whose tumors have a mutation leading to MET exon 14 skipping
Patient support services
• Novartis Oncology Universal Co-pay Program
  877-577-7756
  
  Patient Assistance Now Oncology
  800-282-7630
  
  Novartis Patient Assistance Foundation
  800-277-2254
  
  Tabrecta 14-Day Free Trial Program
  800-282-7630

Drug name (generic name)
• Tagrisso (osimertinib) Tablets
Drug company
• AstraZeneca
Indication
• Adjuvant therapy after tumor resection of NSCLC and EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test
  
  First-line or adjuvant treatment of patients with metastatic NSCLC and EGFR exon 19 deletions or exon 21 L858R substitution mutations
  
  Metastatic NSCLC with EGFR T790M mutation
Patient support services
• Tagrisso Co-pay Savings Program
  844-275-2360
  
  AZ&Me Prescription Savings Program
  800-292-6363

Drug name (generic name)
• Tarceva (erlotinib) Tablets
Drug company
• Genentech
Indication
• Treatment of metastatic NSCLC and EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test, in patients whose cancer is progressing after at least 1 previous chemotherapy regimen
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Tecentriq (atezolizumab)
Drug company
• Genentech
Indication
• First-line treatment of metastatic NSCLC and high PD-L1 expression, as determined by an FDAapproved test, and no EGFR or ALK mutations
  
  Treatment of metastatic NSCLC that progressed during or after platinum-containing chemotherapy; patients with EGFR or ALK mutations should have disease progression with FDA-approved therapy for NSCLC and these mutations before receiving Tecentriq
  
  First-line treatment, in combination with Avastin and chemotherapy, for metastatic nonsquamous NSCLC and no EGFR or ALK mutations
  
  First-line treatment of metastatic nonsquamous NSCLC and no EGFR or ALK mutations, in combination with Abraxane and carboplatin
  
  First-line treatment of extensive-stage small-cell lung cancer, in combination with carboplatin and etoposide
  
  Adjuvant treatment, after resection and platinum-based chemotherapy, of patients with stage II-IIIA NSCLC
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Tepmetko (tepotinib) Tablets
Drug company
• EMD Serono
Indication
• Treatment of adults with metastatic NSCLC and MET exon 14 skipping alterations
Patient support services
• ONC Co-Pay Assistance Program
  844-662-3631
  
  ONC Patient Assistance Program
  844-662-3631
  
  Bridge Program
  844-662-3631

Drug name (generic name)
• Vizimpro (dacomitinib) Tablets
Drug company
• Pfizer
Indication
• Metastatic NSCLC and EGFR exon 19 deletion or exon 21 L858R substitution mutations
Patient support services
• Pfizer Oncology Together Co-Pay Savings Program
  877-744-5675
  
  Pfizer Patient Assistance Program
  877-744-5675

Drug name (generic name)
• Xalkori (crizotinib) Capsules
Drug company
• Pfizer
Indication
• Metastatic NSCLC with ALK or ROS1 mutations
  
  Treatment of locally advanced or metastatic NSCLC that is ALK-positive
Patient support services
• Pfizer Oncology Together Co-Pay Savings Program
  877-744-5675
  
  Pfizer Patient Assistance Program
  877-744-5675

Drug name (generic name)
• Yervoy (ipilimumab)
Drug company
• Bristol Myers Squibb
Indication
• First-line treatment, with Opdivo, of metastatic NSCLC and PD-L1 expression, as determined by an FDA-approved test, and no EGFR or ALK mutations
  
  Treatment, with Opdivo and 2 cycles of chemotherapy, of metastatic or recurrent NSCLC and no EGFR or ALK mutations
  
  Treatment of metastatic NSCLC that progressed during or after platinum-based chemotherapy
  
  First-line treatment, with Opdivo, of unresectable malignant pleural mesothelioma
Patient support services
• BMS Oncology Co-pay Assistance Program
  800-861-0048
  
  Bristol Myers Squibb Patient Assistance Foundation
  800-736-0003

Drug name (generic name)
• Zepzelca (lurbinectedin) Injection
Drug company
• Jazz Pharmaceuticals
Indication
• Metastatic small-cell lung cancer that progressed during or after platinum-based chemotherapy
Patient support services
• JazzCares Copay Savings Card
  833-533-5299
  
  JazzCares Patient Assistance Program
  833-533-5299

Drug name (generic name)
• Zirabev (bevacizumab-bvzr)
Drug company
• Pfizer
Indication
• First-line treatment, in combination with carboplatin and paclitaxel, of unresectable, locally advanced, recurrent or metastatic non-squamous NSCLC
Patient support services
• Pfizer Oncology Together Co-Pay Savings Program
  877-744-5675
  
  Pfizer Patient Assistance Program
  877-744-5675

Drug name (generic name)
• Zykadia (ceritinib) Capsules
Drug company
• Novartis
Indication
• Metastatic NSCLC with ALK mutation
Patient support services
• Patient Assistance Now Oncology
  800-282-7630
  
  Novartis Oncology Universal Co-Pay Program
  877-577-7756
  
  Novartis Patient Assistance Foundation
  800-277-2254

NSCLC indicates non–small-cell lung cancer.